Bench-to-bedside review: Preventive measures for contrast-induced nephropathy in critically ill patients

Critical Care

Volumn 9, Issue 4, 2005, Pages 361-370

  van den Berk, Guido ^a   Tonino, Sanne ^a   de Fijter, Carola ^a   Smit, Watske ^b   Schultz, Marcus J ^b  

^a Onze Lieve Vrouwe Gasthuis ^*  (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ACICLOVIR; AMINOGLYCOSIDE; AMPHOTERICIN B; ANTIVIRUS AGENT; BICARBONATE; CONTRAST MEDIUM; FENOLDOPAM; FOSCARNET; GLUCOSE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; SODIUM CHLORIDE; THEOPHYLLINE;

CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CRITICAL ILLNESS; DEHYDRATION; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIAGNOSTIC IMAGING; DISEASE ASSOCIATION; DIURESIS; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; FLUID THERAPY; HEMODIALYSIS; HUMAN; HYDRATION; IMAGING SYSTEM; INCIDENCE; INTENSIVE CARE UNIT; KIDNEY DISEASE; KIDNEY FAILURE; MEDICAL LITERATURE; MEDLINE; META ANALYSIS; MULTIPLE MYELOMA; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; SYSTEMATIC REVIEW;

ACETYLCYSTEINE; CONTRAST MEDIA; CRITICAL CARE; FENOLDOPAM; FREE RADICAL SCAVENGERS; HEMOFILTRATION; HUMANS; KIDNEY DISEASES; SODIUM BICARBONATE; THEOPHYLLINE; TREATMENT OUTCOME; VASODILATOR AGENTS;

EID: 23744449595     PISSN: 13648535     EISSN: None     Source Type: Journal    
DOI: 10.1186/cc3028     Document Type: Review

References (71)

1. Barrett BJ, Parfrey PS: Prevention of nephrotoxicity induced by radiocontrast agents. N Engl J Med 1994, 331:1449-1450
2. Thomsen HS, Morcos SK: Contrast media and the kidney: European Society of Urogenital Radiology (ESUR) guidelines. Br J Radiol 2003, 76:513-518.
3. Rich MW, Crecelius CA: Incidence, risk factors, and clinical course of acute renal insufficiency after cardiac catheterization in patients 70 years of age or older. A prospective study. Arch Intern Med 1990, 150:1237-1242.
4. Soma VR, Cavusoglu E, Vidhun R, Frishman WH, Sharma SK: Contrast-associated nephropathy. Heart Dis 2002, 4:372-379.
5. McCullough PA, Wolyn R, Rocher LL, Levin RN, O'Neill WW: Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. Am J Med 1997, 103: 368-375.
6. Gruberg L, Mintz GS, Mehran R, Gangas G, Lansky AJ, Kent KM, Pichard AD, Satler LF, Leon MB: The prognostic implications of further renal function deterioration within 48 h of interventional coronary procedures in patients with pre-existent chronic renal insufficiency. J Am Coll Cardiol 2000, 36:1542-1548.
7. Levy EM, Viscoli CM, Horwitz RI: The effect of acute renal failure on mortality. A cohort analysis. JAMA 1996, 275:1489-1494.
8. Rihal CS, Textor SC, Grill DE, Berger PB, Ting HH, Best PJ, Singh M, Bell MR, Barsness GW, Mathew V, et al.: Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation 2002, 105:2259-2264.
9. Aronow HD, Peyser PA, Eagle KA, Bates ER, Werns SW, Russman PL, Crum MA, Harris K, Moscucci M: Predictors of length of stay after coronary stenting. Am Heart J 2001, 142: 799-805.
10. Manske CL, Sprafka JM, Strony JT, Wang Y: Contrast nephropathy in azotemic diabetic patients undergoing coronary angiography. Am J Med 1990, 89:615-620.
11. Weisberg LS, Kurnik PB, Kurnik BR: Risk of radiocontrast nephropathy in patients with and without diabetes mellitus. Kidney Int 1994, 45:259-265.
12. Mueller C, Buerkle G, Buettner HJ, Petersen J, Perruchoud AP, Eriksson U, Marsch S, Roskamm H: Prevention of contrast media-associated nephropathy: randomized comparison of 2 hydration regimens in 1620 patients undergoing coronary angioplasty. Arch Intern Med 2002, 162:329-336.
13. Oldemeyer JB, Biddle WP, Wurdeman RL, Mooss AN, Cichowski E, Hilleman DE: Acetylcysteine in the prevention of contrast-induced nephropathy after coronary angiography. Am Heart J 2003, 146:E23.
14. Morcos SK, Thomsen HS, Webb JA: Contrast-media-induced nephrotoxicity: a consensus report. Contrast Media Safety Committee, European Society of Urogenital Radiology (ESUR). Eur Radiol 1999, 9:1602-1613.
15. Tepel M, Zidek W, van der Giet M, Schwarzfeld C, Laufer U, Liermann D: Acetylcysteine and contrast media nephropathy. Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. Curr Opin Nephrol Hypertens 2002, 11:503-506.
16. Birck R, Krzossok S, Markowetz F, Schnulle P, van der Woude FJ, Braun C: Acetylcysteine for prevention of contrast nephropathy: meta-analysis. Lancet 2003, 362:598-603.
17. Isenbarger DW, Kent SM, O'Malley PG: Meta-analysis of randomized clinical trials on the usefulness of acetylcysteine for prevention of contrast nephropathy. Am J Cardiol 2003, 92: 1454-1458.
18. Alonso A, Lau J, Jaber BL, Weintraub A, Sarnak MJ: Prevention of radiocontrast nephropathy with N-acetylcysteine in patients with chronic kidney disease: a meta-analysis of randomized, controlled trials. Am J Kidney Dis 2004, 43:1-9.
19. Asif A, Epstein M: Prevention of radiocontrast-induced nephropathy. Am J Kidney Dis 2004, 44:12-24.
20. Walker PD, Brokering KL, Theobald JC: Fenoldopam and Nacetylcysteine for the prevention of radiographic contrast material-induced nephropathy: a review. Pharmacotherapy 2003, 23:1617-1626.
21. Morcos SK: Prevention of contrast media nephrotoxicity: the story so far. Clin Radiol 2004, 59:381-389.
22. Tepel M, van der Giet M, Schwarzfeld C, Laufer U, Liermann D, Zidek W: Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med 2000, 343:180-184.
23. Allaqaband S, Tumuluri R, Malik AM, Gupta A, Volkert P, Shalev Y, Bajwa TK: Prospective randomized study of N-acetylcysteine, fenoldopam, and saline for prevention of radiocontrast-induced nephropathy. Catheter Cardiovasc Interv 2002, 57:279-283.
24. Briguori C, Manganelli F, Scarpato P, Elia PP, Golia B, Riviezzo G, Lepore S, Librera M, Villari B, Colombo A, et al.: Acetylcysteine and contrast agent-associated nephrotoxicity. J Am Coll Cardiol 2002, 40:298-303.
25. Diaz-Sandoval LJ, Kosowsky BD, Losordo DW: Acetylcysteine to prevent angiography-related renal tissue injury (the APART trial). Am J Cardiol 2002, 89:356-358.
26. Durham JD, Caputo C, Dokko J, Zaharakis T, Pahlavan M, Keltz J, Dutka P, Marzo K, Maesaka JK, Fishbane S: A randomized controlled trial of Nacetylcysteine to prevent contrast nephropathy in cardiac angiography. Kidney Int 2002, 62:2202-2207.
27. Shyu KG, Cheng JJ, Kuan P: Acetylcysteine protects against acute renal damage in patients with abnormal renal function undergoing a coronary procedure. J Am Coll Cardiol 2002, 40: 1383-1388.
28. Baker CS, Wragg A, Kumar S, De Palma R, Baker LR, Knight CJ: A rapid protocol for the prevention of contrast-induced renal dysfunction: the RAPPID study. J Am Coll Cardiol 2003, 41: 2114-2118.
29. Boccalandro F, Amhad M, Smalling RW, Sdringola S: Oral acetylcysteine does not protect renal function from moderate to high doses of intravenous radiographic contrast. Catheter Cardiovasc Interv 2003, 58:336-341.
30. Kay J, Chow WH, Chan TM, Lo SK, Kwok OH, Yip A, Fan K, Lee CH, Lam WF: Acetylcysteine for prevention of acute deterioration of renal function following elective coronary angiography and intervention: a randomized controlled trial. JAMA 2003, 289:553-558.
31. Kefer JM, Hanet CE, Boitte S, Wilmotte L, De Kock M: Acetylcysteine, coronary procedure and prevention of contrast-induced worsening of renal function: which benefit for which patient? Acta Cardiol 2003, 58:555-560.
32. MacNeill BD, Harding SA, Bazari H, Patton KK, Colon-Hernadez P, DeJoseph D, Jang IK: Prophylaxis of contrast-induced nephropathy in patients undergoing coronary angiography. Catheter Cardiovasc Interv 2003, 60:458-461.
33. Briguori C, Colombo A, Violante A, Balestrieri P, Manganelli F, Paolo Elia P, Golia B, Lepore S, Riviezzo G, Scarpato P, et al.: Standard vs double dose of Nacetylcysteine to prevent contrast agent associated nephrotoxicity. Acetylcysteine and contrast agent-associated nephrotoxicity. Eur Heart J 2004, 25:206-211.
34. Fung JW, Szeto CC, Chan WW, Kum LC, Chan AK, Wong JT, Wu EB, Yip GW, Chan JY, Yu CM, et al.: Effect of Nacetylcysteine for prevention of contrast nephropathy in patients with moderate to severe renal insufficiency: a randomized trial. Am J Kidney Dis 2004, 43:801-808.
35. Goldenberg I, Shechter M, Matetzky S, Jonas M, Adam M, Pres H, Elian D, Agranat O, Schwammenthal E, Guetta V: Oral acetylcysteine as an adjunct to saline hydration for the prevention of contrast-induced nephropathy following coronary angiography. A randomized controlled trial and review of the current literature. Eur Heart J 2004, 25:212-218.
36. Briguori C, Colombo A, Airoldi F, Violante A, Castelli A, Balestrieri P, Paolo Elia P, Golia B, Lepore S, Riviezzo G, et al.: N-Acetylcysteine versus fenoldopam mesylate to prevent contrast agent-associated nephrotoxicity. J Am Coll Cardiol 2004, 44:762-765.
37. Merten GJ, Burgess WP, Gray LV, Holleman JH, Roush TS, Kowalchuk GJ, Bersin RM, Van Moore A, Simonton CA 3rd, Rittase RA, et al.: Prevention of contrast-induced nephropathy with sodium bicarbonate: a randomized controlled trial. JAMA 2004, 291:2328-2334.
38. Erley CM, Duda SH, Schlepckow S, Koehler J, Huppert PE, Strohmaier WL, Bohle A, Risler T, Osswald H: Adenosine antagonist theophylline prevents the reduction of glomerular filtration rate after contrast media application. Kidney Int 1994, 45: 1425-1431.
39. Katholi RE, Taylor GJ, McCann WP, Woods WT Jr, Womack KA, McCoy CD, Katholi CR, Moses HW, Mishkel GJ, Lucore CL, et al.: Nephrotoxicity from contrast media: attenuation with theophylline. Radiology 1995, 195:17-22.
40. Kolonko A, Wiecek A, Kokot F: The nonselective adenosine antagonist theophylline does prevent renal dysfunction induced by radiographic contrast agents. J Nephrol 1998, 11: 151-156.
41. Abizaid AS, Clark CE, Mintz GS, Dosa S, Popma JJ, Pichard AD, Satler LF, Harvey M, Kent KM, Leon MB: Effects of dopamine and aminophylline on contrast-induced acute renal failure after coronary angioplasty in patients with preexisting renal insufficiency. Am J Cardiol 1999, 83:260-263, A265.
42. Erley CM, Duda SH, Rehfuss D, Scholtes B, Bock J, Muller C, Osswald H, Risler T: Prevention of radiocontrast-media-induced nephropathy in patients with pre-existing renal insufficiency by hydration in combination with the adenosine antagonist theophylline. Nephrol Dial Transplant 1999, 14:1146-1149.
43. Huber W, Jeschke B, Page M, Weiss W, Salmhofer H, Schweigart U, Ilgmann K, Reichenberger J, Neu B, Classen M: Reduced incidence of radiocontrast-induced nephropathy in ICU patients under theophylline prophylaxis: a prospective comparison to series of patients at similar risk. Intensive Care Med 2001, 27:1200-1209.
44. Huber W, Ilgmann K, Page M, Hennig M, Schweigart U, Jeschke B, Lutilsky L, Weiss W, Salmhofer H, Classen M: Effect of theophylline on contrast material-nephropathy in patients with chronic renal insufficiency: controlled, randomized, double-blinded study. Radiology 2002, 223:772-779.
45. Kapoor A, Kumar S, Gulati S, Gambhir S, Sethi RS, Sinha N: The role of theophylline in contrast-induced nephropathy: a case-control study. Nephrol Dial Transplant 2002, 17:1936-1941.
46. Huber W, Schipek C, Ilgmann K, Page M, Hennig M, Wacker A, Schweigart U, Lutilsky L, Valina C, Seyfarth M, et al.: Effectiveness of theophylline prophylaxis of renal impairment after coronary angiography in patients with chronic renal insufficiency. Am J Cardiol 2003, 91:1157-1162.
47. Kini AA, Sharma SK: Managing the high-risk patient: experience with fenoldopam, a selective dopamine receptor agonist, in prevention of radiocontrast nephropathy during percutaneous coronary intervention. Rev Cardiovasc Med 2001, 2: S19-S25.
48. Tumlin JA, Wang A, Murray PT, Mathur VS: Fenoldopam mesylate blocks reductions in renal plasma flow after radiocontrast dye infusion: a pilot trial in the prevention of contrast nephropathy. Am Heart J 2002, 143:894-903.
49. Stone GW, McCullough PA, Tumlin JA, Lepor NE, Madyoon H, Murray P, Wang A, Chu AA, Schaer GL, Stevens M, et al.: Fenoldopam mesylate for the prevention of contrast-induced nephropathy: a randomized controlled trial. JAMA 2003, 290: 2284-2291.
50. Vogt B, Ferrari P, Schonholzer C, Marti HP, Mohaupt M, Wiederkehr M, Cereghetti C, Serra A, Huynh-Do U, Uehlinger D, et al.: Prophylactic hemodialysis after radiocontrast media in patients with renal insufficiency is potentially harmful. Am J Med 2001, 111:692-698.
51. Marenzi G, Bartorelli AL, Lauri G, Assanelli E, Grazi M, Campodonico J, Marana I: Continuous veno-venous hemofiltration for the treatment of contrast-induced acute renal failure after percutaneous coronary interventions. Catheter Cardiovasc Interv 2003, 58:59-64.
52. Marenzi G, Marana I, Lauri G, Assanelli E, Grazi M, Campodonico J, Trabattoni D, Fabbiocchi F, Montorsi P, Bartorelli AL: The prevention of radiocontrast-agent-induced nephropathy by hemofiltration. N Engl J Med 2003, 349:1333-1340.
53. Frank H, Werner D, Lorusso V, Klinghammer L, Daniel WG, Kunzendorf U, Ludwig J: Simultaneous hemodialysis during coronary angiography fails to prevent radiocontrast-induced nephropathy in chronic renal failure. Clin Nephrol 2003, 60: 176-182.
54. Weisberg LS, Kurnik PB, Kurnik BR: Radiocontrast-induced nephropathy in humans: role of renal vasoconstriction. Kidney Int 1992, 41:1408-1415.
55. Solomon R: Contrast-medium-induced acute renal failure. Kidney Int 1998, 53:230-242.
56. Rudnick MR, Goldfarb S: Pathogenesis of contrast-induced nephropathy: experimental and clinical observations with an emphasis on the role of osmolality. Rev Cardiovasc Med 2003, Suppl 5:S28-S33.
57. Moreau JF, Droz D, Noel LH, Leibowitch J, Jungers P, Michel JR: Tubular nephrotoxicity of water-soluble iodinated contrast media. Invest Radiol 1980, 15:S54-S60.
58. Moreau JF, Noel LH, Droz D: Proximal renal tubular vacuolization induced by iodinated contrast media, or so-called 'osmotic nephrosis'. Invest Radiol 1993, 28:187-190.
59. Baliga R, Ueda N, Walker PD, Shah SV: Oxidant mechanisms in toxic acute renal failure. Am J Kidney Dis 1997, 29:465-477.
60. Yoshioka T, Fogo A, Beckman JK: Reduced activity of antioxidant enzymes underlies contrast media-induced renal injury in volume depletion. Kidney Int 1992, 41:1008-1015.
61. Bakris GL, Lass N, Gaber AO, Jones JD, Burnett JC Jr: Radiocontrast medium-induced declines in renal function: a role for oxygen free radicals. Am J Physiol 1990, 258:F115-F120.
62. Caldicott WJ, Hollenberg NK, Abrams HL: Characteristics of response of renal vascular bed to contrast media. Evidence for vasoconstriction induced by renin-angiotensin system. Invest Radiol 1970, 5:539-547.
63. Katzberg RW, Morris TW, Burgener FA, Kamm DE, Fischer HW: Renal renin and hemodynamic responses to selective renal artery catheterization and angiography. Invest Radiol 1977, 12: 381-388.
64. Corradi A, Menta R, Cambi V, Maccarini P, Cerutti R: Pharmacokinetics of iopamidol in adults with renal failure. Arzneimittelforschung 1990, 40:830-832.
65. Waaler A, Svaland M, Fauchald P, Jakobsen JA, Kolmannskog F, Berg KJ: Elimination of iohexol, a low osmolar nonionic contrast medium, by hemodialysis in patients with chronic renal failure. Nephron 1990, 56:81-85.
66. Ueda J, Furukawa T, Takahashi S, Sakaguchi K: Elimination of ioversol by hemodialysis. Acta Radiol 1996, 37:826-829.
67. Furukawa T, Ueda J, Takahashi S, Sakaguchi K: Elimination of low-osmolality contrast media by hemodialysis. Acta Radiol 1996, 37:966-971.
68. Schindler R, Stahl C, Venz S, Ludat K, Krause W, Frei U: Removal of contrast media by different extracorporeal treatments. Nephrol Dial Transplant 2001, 16:1471-1474.
69. Hoffmann U, Banas B, Fischereder M, Kramer BK: N-acetylcysteine in the prevention of radiocontrast-induced nephropathy: clinical trials and end points. Kidney Blood Press Res 2004, 27: 161-166.
70. Hoffmann U, Fischereder M, Kruger B, Drobnik W, Kramer BK: The value of N-acetylcysteine in the prevention of radiocontrast agent-induced nephropathy seems questionable. J Am Soc Nephrol 2004, 15:407-410.
71. Block CA, Manning HL: Prevention of acute renal failure in the critically ill. Am J Respir Crit Care Med 2002, 165:320-324.